The AEBP2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat T lymphocytes, featuring targeted disruption of the AEBP2 gene. This polyclonal pool retains genetic heterogeneity and eschews clonal isolation, providing a robust loss-of-function system for studying AEBP2-dependent epigenetic regulation at the population level, particularly useful for high-throughput screens and integrative analyses.
Jurkat cells are a well-established human T-cell leukemia line originally isolated from an acute T-cell leukemia patient. These suspension-adapted lymphoblasts serve as a canonical model for T-cell receptor signaling, apoptosis, and leukemogenesis, and are extensively employed in immunological and oncology research due to their reproducible growth and well-characterized signaling networks.
AEBP2 is an auxiliary cofactor of Polycomb repressive complex 2 (PRC2) that interacts with core subunits EZH2, SUZ12, EED, RBBP4, and RBBP7 to enhance histone H3 lysine 27 trimethylation (H3K27me3), a repressive chromatin mark. This activity facilitates transcriptional silencing of target genes, including tumor suppressor loci such as CDKN2A (p16INK4a/p14ARF). AEBP2 also associates with accessory factors like JARID2, modulating PRC2 recruitment or stability. Upstream regulation may involve developmental transcriptional programs and post-translational modifications, placing AEBP2 within a broader PRC2?CPRC1 silencing axis that governs differentiation, proliferation, and malignant transformation.
In Jurkat cells, which exhibit an aberrant epigenetic landscape characteristic of T-cell acute lymphoblastic leukemia, knockout of AEBP2 attenuates PRC2-mediated H3K27me3 deposition, resulting in derepression of PRC2 target genes. This perturbation enables mechanistic dissection of AEBP2??s contribution to leukemic proliferation, survival, and drug sensitivity, and offers a tractable platform for examining context-specific PRC2 functions in T-cell malignancies.
Researchers can employ this model in chromatin immunoprecipitation (ChIP-qPCR) to map H3K27me3 changes, co-immunoprecipitation assays to verify AEBP2?CPRC2 associations, and western blotting to assess histone modification levels. Functional readouts including proliferation, apoptosis, and flow cytometric immunophenotyping can be coupled with RNA-seq and RT-qPCR to capture transcriptional alterations. Additionally, the cells are suitable for screening small-molecule inhibitors of EZH2 or other PRC2 components, and for investigating differentiation pathways in leukemia contexts. For technical support or customized applications, please contact Ascent Research.
